- Dr. Brown previously served as Head of Global Pharmaceutical Development at Galderma and has over 25 years of experience leading clinical development programs
- Dermavant plans to initiate Phase 3 clinical program for tapinarof in first half of 2019
BASEL, Switzerland, Jan. 2, 2019 -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Philip M. Brown, M.D., J.D., as Chief Medical Officer. Dr. Brown has over 25 years of experience leading clinical development programs. He most recently served as head of global pharmaceutical drug development at Galderma, the pharmaceutical subsidiary of Nestlé Skin Health.
“Phil joins Dermavant at a critical time in the company’s evolution, as we prepare to initiate our Phase 3 program evaluating tapinarof in psoriasis,” said Todd Zavodnick, Chief Executive Officer of Dermavant. “Phil has the expertise and the judgment necessary to take tapinarof forward while simultaneously advancing our pipeline for other prevalent skin conditions.”
“It is a privilege to join the Dermavant team,” said Dr. Brown. “Dermavant has one of the most innovative medical dermatology pipelines in the industry, and I look forward to overseeing the advancement of investigational medicines which address true unmet needs.”
Prior to joining Galderma, Dr. Brown served as senior vice president of clinical development at Lexicon Pharmaceuticals, a publicly-traded biopharmaceutical company engaged in the discovery and development of treatments using proprietary gene knockout technology. Dr. Brown also has served in other clinical development leadership roles in both public and private biotechnology companies. He received his M.D. from Texas Tech University Health Science Center School of Medicine, his J.D. from the University of Texas School of Law, and his B.A. from Hendrix College.
Dermavant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. The company’s development pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing markets, psoriasis and atopic dermatitis, as well as other large markets, including acne, primary focal hyperhidrosis, and vitiligo. Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a potentially first-in-class therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of psoriasis and atopic dermatitis, which affect approximately 7.5 million and 28 million people in the United States, respectively.
For more information about Dermavant, please visit www.dermavant.com.